Anteris Technologies closes $320 million stock offering and private placement

Anteris Technologies Global Corp. (NASDAQ: AVR) completed a $230 million public offering of common stock and a separate private placement with Medtronic plc, raising approximately $320 million in gross proceeds before fees and expenses.

The company sold 40 million shares in the public offering at $5.75 per share, including shares from the full exercise of underwriters' option to purchase additional shares. Separately, Anteris sold 15.7 million shares to Medtronic at the same price of $5.75 per share through a private placement.

Barclays, Wells Fargo Securities and Cantor served as joint book-running managers for the public offering. Wells Fargo Securities acted as placement agent for the Medtronic transaction.

Anteris stated it plans to use the net proceeds to support its clinical strategy, including ongoing recruitment for its DurAVR Transcatheter Heart Valve global pivotal trial for patients with severe aortic stenosis, known as the PARADIGM Trial. The funds will also support expansion of manufacturing capabilities and research and development for v2vmedtech, inc., with remaining proceeds allocated to working capital and general corporate purposes.

The public offering was conducted under a shelf registration statement that became effective on January 8, 2026. The shares sold in the private placement to Medtronic were not registered under the Securities Act.

Anteris develops medical devices for structural heart disease treatment. The company's lead product, DurAVR THV, is designed to treat aortic stenosis and is currently being evaluated in clinical trials. The first patients were enrolled in the PARADIGM Trial in Denmark during the fourth quarter of 2025.

You May Also Be Interested In

• MicroVision launches public offering of shares and warrants
• MapLight Therapeutics raises $150M in private placement
• Hyperscale Data sets 1-for-5 reverse stock split for Aug. 24